ABSTRACT
Objective: To assess the efficacy and safety of loxapine in acute agitation.
Data Sources: PubMed, Cochrane database, EMBASE, PsycINFO, and ClinicalTrials.gov were searched to identify relevant articles published in English or French from inception to March 15, 2022. The term “Loxap*” was searched in titles and abstracts.
Study Selection and Data Extraction: Interventional studies that compared the effectiveness of loxapine to any other intervention (including another administration route or dosage of loxapine, other drugs, and placebo) in acute agitation were included. From the 1,435 articles initially identified, and after the assessment of 73 full texts, 7 articles were selected, encompassing 1,276 participants. Two reviewers independently extracted data of interest using a predefined form.
Results: Among included studies, 5 were double-blind, 2 were open-label, and all were randomized. The risk of bias was low for 2 studies, involving 658 participants. Four articles compared loxapine to placebo, and 3 compared it with haloperidol, aripiprazole, and droperidol. Loxapine was found to be more effective and faster regarding acute agitation control. Also, across included studies, loxapine was well-tolerated, with mildly or moderately severe adverse effects.
Conclusions: Notwithstanding methodological limitations of the included studies, this systematic review provides reassuring results regarding the use of loxapine in acute agitation. However, further studies with methodological optimizations might be of interest.
Prim Care Companion CNS Disord 2023;25(6):23r03552
Author affiliations are listed at the end of this article.
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (37)
- Crocq MA, Guelfi JD. DSM-5: Manuel Diagnostique et Statistique des Troubles Mentaux. Fifth Edition. Issy-les-Moulineaux: Elsevier Masson; 2015.
- Hall RCW, Gardner ER, Stickney SK, et al. Physical illness manifesting as psychiatric disease, II: analysis of a state hospital inpatient population. Arch Gen Psychiatry. 1980;37(9):989–995. PubMed CrossRef
- Gregory RJ, Nihalani ND, Rodriguez E. Medical screening in the emergency department for psychiatric admissions: a procedural analysis. Gen Hosp Psychiatry. 2004;26(5):405–410. PubMed CrossRef
- Koran LM, Sheline Y, Imai K, et al. Medical disorders among patients admitted to a public-sector psychiatric inpatient unit. Psychiatr Serv. 2002;53(12):1623–1625. PubMed CrossRef
- Nordstrom K, Zun LS, Wilson MP, et al. Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup. West J Emerg Med. 2012;13(1):3–10. PubMed CrossRef
- Roppolo LP, Morris DW, Khan F, et al. Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation). J Am Coll Emerg Physicians Open. 2020;1(5):898–907. PubMed CrossRef
- Haute Autorité de Santé. Guide méthodologique : Mieux prévenir et prendre en charge les moments de violence dans l’évolution clinique des patients adultes lors des hospitalisations en service de psychiatrie [Internet]. 2016. Accessed April 8, 2023. https://www.has-sante.fr/upload/docs/application/pdf/2016-10/guide_methodo_violence_hospi_psy.pdf
- Gerson R, Malas N, Feuer V, et al. Best practices for evaluation and treatment of agitated children and adolescents (BETA) in the emergency department: consensus statement of the american association for emergency psychiatry. West J Emerg Med. 2019;20(2):409–418. PubMed CrossRef
- Légifrance. Article 84 - LOI n° 2020-1576 du 14 décembre 2020 de financement de la sécurité sociale pour [Internet]. Accessed April 8, 2023. https://www.legifrance.gouv.fr/jorf/article_jo/JORFARTI000042665379#:~:text=%2DLa%20mesure%20d%27isolement%20est,totale%20de%20quarante%2Dhuit%20heures
- Légifrance. Article L3222-5-1 - Code de la santé publique [Internet]. Accessed April 8, 2023. https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000031918948
- SFMU. (Société Française de Médecine d’Urgence). Conférence de Consensus : “ L’agitation en urgence (petit enfant excepté) ” [Internet]. 2003. Accessed April 8, 2023. https://www.sfmu.org/upload/consensus/cc_agitation-court.pdf
- SFMU. (Société Française de Médecine d’Urgence). Recommandations de Bonne Pratique Clinique. Prise en charge du patient adulte à présentation psychiatrique dans les structures d’urgences [Internet]. 2021. https://www.sfmu.org/upload/consensus/rbpc-psychiatrie_sfmu2021.pdf
- Bourdinaud V, Pochard F. Survey of management methods for patients in a state of agitation at admission and emergency departments in France. Encephale. 2003;29(2):89–98. PubMed
- Chakrabarti A, Bagnall A, Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007;2007(4):CD001943. PubMed
- Drug Approval Package. Adasuve (loxapine) NDA #022549 [Internet]. Accessed April 8, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022549_adasuve_toc.cfm
- de Berardis D, Fornaro M, Orsolini L, et al. The role of inhaled loxapine in the treatment of acute agitation in patients with psychiatric disorders: a clinical review. Int J Mol Sci. 2017;18(2):349. PubMed CrossRef
- Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. PubMed CrossRef
- Barbic D, Andolfatto G, Grunau B, et al. Rapid agitation control with ketamine in the emergency department: a blinded, randomized controlled trial. Ann Emerg Med. 2021;78(6):788–795. PubMed CrossRef
- Muir-Cochrane E, Oster C, Gerace A, et al. The effectiveness of chemical restraint in managing acute agitation and aggression: a systematic review of randomized controlled trials. Int J Ment Health Nurs. 2020;29(2):110–126. PubMed CrossRef
- deSouza IS, Thode HC Jr, Shrestha P, et al. Rapid tranquilization of the agitated patient in the emergency department: a systematic review and network meta-analysis. Am J Emerg Med. 2022;51:363–373. PubMed CrossRef
- Page MJ, McKenzie JE, Bossuyt PM, et al. Declaracion PRISMA 2020: Una Guia Actualizada Para La Publicacion De Revisiones Sistematicas. (The PRISMA 2020 statement: an updated guideline for reporting systematic reviews). Rev Esp Cardiol (Engl Ed). 2021;74(9):790–799.
- Risk of Bias 2 (RoB 2) tool | Cochrane Methods [Internet]. Accessed September 15, 2022. https://methods.cochrane.org/risk-bias-2
- Fruensgaard K, Korsgaard S, Jorgensen H, et al. Loxapine versus haloperidol parenterally in acute psychosis with agitation: a double-blind study. Acta Psychiatr Scand. 1977;56(4):256–264. PubMed CrossRef
- Gaussares C, Gerard H, Bosc M. Interest in injectable loxapine in severe agitation states. (French) Inf Psychiatr. 1989;65(6):656–660.
- Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313–1321. PubMed CrossRef
- Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–58. PubMed CrossRef
- Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31–40. PubMed CrossRef
- Gaudry S, Sztrymf B, Sonneville R, et al. Loxapine to control agitation during weaning from mechanical ventilation. Crit Care. 2017;21(1):235. PubMed CrossRef
- San L, Estrada G, Oudovenko N, et al. PLACID study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;28(6):710–718. PubMed CrossRef
- Popovic D, Nuss P, Vieta E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14(1):15. PubMed CrossRef
- Ruch T, Nuss S, Yeruva RR, et al. Inhaled loxapine for acute agitation in a psychiatric emergency service. Ann Clin Psychiatry. 2021;33(3):162–167. PubMed CrossRef
- McDowell M, Nitti K, Kulstad E, et al. Clinical outcomes in patients taking inhaled loxapine, haloperidol, or ziprasidone in the emergency department. Clin Neuropharmacol. 2019;42(2):23–26. PubMed CrossRef
- Ferrer M, Soto-Angona Ó, Soler-Artigas M, Ibáñez P, Fadeuilhe C, Palma-Álvarez RF, et al. Inhaled loxapine as a rapid treatment for agitation in patients with personality disorder: a prospective study on the effects of time. 2022;20(3):482–490.
- Roncero C, Ros-Cucurull E, Palma-Álvarez RF, et al. Inhaled loxapine for agitation in intoxicated patients: A case series. Clin Neuropharmacol. 2017;40(6):281–285. PubMed CrossRef
- Reinblatt SP, Abanilla PK, Jummani R, et al. Loxapine treatment in an autistic child with aggressive behavior: therapeutic challenges. J Child Adolesc Psychopharmacol. 2006;16(5):639–643. PubMed CrossRef
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
- Montoya A, Valladares A, Lizán L, et al. Validation of the excited component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9(1):18. PubMed CrossRef
Please sign in or purchase this PDF for $40.
Save
Share
Cite
